GERONJPM-2025-Corporate-Slides_final-2

Corporate PresentationOur mission is to change lives by changing the course of blood cancerJanuary 2025Our mission is to change lives by changing the course of blood cancer2Forward-Looking StatementsExcept for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the Company’s belief that RYTELO is a highly differentiated treatment with blockbuster potential for eligible LR-MDS patients, including the potential to achieve $1B+ in net revenue; (ii) the Company’s estimate of net revenues for the fourth quarter of 2024; (iii) the Company’s views, estimates and expectations concerning the commercial launch of RYTELO, including the size of market opportunity and ability to compete for market share; (iv) the Company’s assumptions and expectations rega